INIFY Laboratories AB
OSE:INIFY
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SE |
I
|
INIFY Laboratories AB
OSE:INIFY
|
307.7m NOK |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
97.3B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
65.2B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
74.6B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
29.3B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
24.2B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.3B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.2B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.9B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.9B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD |
Loading...
|
Market Distribution
| Min | -855 316.7% |
| 30th Percentile | 30.8% |
| Median | 44.8% |
| 70th Percentile | 66% |
| Max | 113 764.6% |
Other Profitability Ratios
INIFY Laboratories AB
Glance View
INIFY Laboratories AB engages in the provision of cancer diagnostics through laboratory services within pathology. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2022-06-20. The firm uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The firm origins from ContextVision.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for INIFY Laboratories AB is 55.3%, which is below its 3-year median of 56.8%.
Over the last 5 months, INIFY Laboratories AB’s Gross Margin has decreased from 58.4% to 55.3%. During this period, it reached a low of 55.3% on Oct 30, 2023 and a high of 58.4% on May 30, 2023.
